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www.cdatm.orgAbstractObjectives: To observe the curative effects and adverse reactions of recombinant human (rh)-endostatin injection combined with a
TP regimen for treating patients with advanced ovarian cancer.
Methods: Fifty-four patients with pathologically confirmed ovarian cancer were randomly divided into a combined treatment
(intravenous pump of rh-endostatinþ TP regimen) group and a control (single chemotherapy) group, twenty-seven patients in each
group. All patients were given a conventional CT examination. The level of vascular endothelial growth factor (VEGF), the size of
tumor before treatment, after 2 cycles and after 4 cycles of treatment were determined for the comparison of curative effects and
adverse reactions.
Results: The effective rate was 37.0% (10/27) and disease control rate was 63.0% (17/27) in the combined treatment group after 2
cycles of treatment. The effective rate was 25.9% (7/27) and disease control rate was 63.0% (17/27) in the control group. The
comparison between these two groups showed no significant differences (P> 0.05). The effective rate was 63.0% (17/27) and disease
control rate was 92.6% (25/27) in the combined treatment group after 4 cycles of treatment. The effective rate was 29.6% (8/27) and
disease control rate was 63.0% (17/27) in the control group. The effective rate and disease control rate between these two groups after
4 cycles of treatment showed significant differences (P < 0.05). The incidences of cardiovascular toxicity, myelosuppression, sore
muscles and joints, alopecia and gastrointestinal reaction was not significantly different between two groups (P > 0.05).
Conclusion: The pump delivery of rh-endostatin can down-regulate the expression of VEGF in ovarian cancer and has the better
curative effect and slighter adverse reactions.* Corresponding author. Tel.: þ86 371 65587697.
E-mail address: zhangc0923@163.com (S.-X. Luo).
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General data of patients with ovarian cancer between the two groups
(n).
Clinical data Combined
treatment group
Control
group
P-value
Pathological pattern >0.05
Serous adenocarcinoma 25 26
Mucinous adenocacinoma 2 1
Clinical stages >0.05
Ⅲc 3 5
Ⅳ 24 22
ECOG score >0.05
0e1 21 24
2 6 3
ECOG: Eastern Cooperative Oncology Group.Introduction
Ovarian cancer is one of the most common malig-
nant tumors; its incidence ranks third among the ma-
lignant tumors of the female genital system and the
death rate is at the top of the gynecologic cancers and
increases year by year.1,2 Tumors can grow fast, invade
surrounding tissues and metastasize to distant sites
through entering the blood circulation only after the
formation of new vessels.3 Endostatin is an endoge-
nous angiogenesis inhibiting factor, based on which
recombinant human (rh)-endostatin, a new artificially
synthesized targeted drug for anti-angiogenesis are
modeled, and it has synergistic effects when combined
with chemotherapeutics.4,5 We observed and analyzed
the efficacy of continuous pump delivery of rh-
endostain with chemotherapy and chemotherapy
alone to investigate a new clinical approach and the
results are as follows.
Materials and methods
Case selection
Inclusion criteria: Patients with ovarian cancer
confirmed by pathology and/or cytology; patients who
had objective measurable primary lesions; stage IV
before treatment according to the criteria of the Inter-
national Federation of Gynecology and Obstetrics
(FIGO) in 2006; generally Eastern Cooperative
Oncology Group (ECOG) scores are 0e2; the exami-
nation indexes confirm chemotherapeutic indications;
no dysfunction of primary organs; drug discontinuance
for more than 4 weeks in case of a history of use of
other chemotherapeutics; an expected survival time 3
months; patients who were willing to accept this
treatment plan and showed good compliance. Exclu-
sion criteria: patients who had no measurable tumor
lesions; pregnant and lactating women; patients with
metastatic tumor to the central nervous system who did
not get effective control; patients who did not complete
the treatment course of chemotherapy; patients who
did not have a CT examination.General data
A total of 54 patients from October 2012 to January
2014 were enrolled for a forward-looking, randomized,
and controlled clinical trial and randomly divided into
a combined treatment group and a control group ac-
cording to the ratio of 1:1. All 54 cases were evaluated.
Age, performance status, clinical stage, and the path-
ological pattern between the two groups were compa-
rable (P > 0.05) (Table 1).
Treatment methods
The combined treatment group received an intra-
venous pump to deliver the rh-endostatin along with
the TP regimen: intravenous drip of paclitaxel and
cisplatin on the first day of each cycle, 75 mg/m2 and
135 mg/m2, respectively, repeated every 21 days. The
control group was given the TP regimen only. The
above plan required completing at least four cycles.
VEGF detection method
Venous blood (10 ml) was drawn before treatment
and after treatment. An enzyme-linked immunosorbent
assay (ELISA) was employed to detect the levels of
VEGF. The above procedures were completed by a
supervising technician according to instruction under
strict quality control.
Table 3
Comparison of the level of VEGF between the two groups
(mean ± SD).
Group Time VEGF (pg/ml)
Combined treatment
group (n ¼ 27)
Treatment before 685.56 ± 41.28
After 2 cycles of treatment 528.09 ± 53.08ab
After 4 cycles of treatment 389.64 ± 55.17ac
Control
group (n ¼ 27)
Treatment before 717.93 ± 48.27
After 2 cycles of treatment 568.43 ± 56.19*
After 4 cycles of treatment 438.86 ± 42.66*
Compared with treatment before, aP < 0.01; compared with control
group after 2 cycles of treatment, bP < 0.05; Compared with control
group after 4 cycles of treatment, cP < 0.05. SD: standard deviation.
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The short-term efficacy of the two groups was
observed. Conventional CT examinations for the size of
tumors were performed. The level of VEGF and the size
of tumors were determined for comparison before
treatment, after 2 cycles, and after 4 cycles of treatment.
Evaluation criterion
The size of the tumor lesion was evaluated ac-
cording to Response Evaluation Criteria in Solid Tu-
mors (RECIST) and divided into complete remission
(CR), partial remission (PR), stability of disease (SD),
and progression of disease (PD). The remission rate
(RR) ¼ CR þ PR, and total stability rate
(TSR) ¼ CR þ PR þ SD. A CT examination was
performed one week before chemotherapy and one
week after the completion of the second and fourth
cycles. Security indexes were evaluated by WHO
antitumor drug acute and subacute toxicity and grading
standard.
Statistical data analysis
The SPSS17.0 software (Chicago IL, USA) was
used for data analysis. A c2 test was used for com-
parison of the two groups and a paired t test for the
differences between before and after treatment.
P < 0.05 was considered to be statistically significant.
Results
Short-term efficacy and safety
Short-term efficacy: There was no CR in patients of
either group after 2 cycles of treatment. Of 27 patients
in the combined treatment group, 10 patients had a PR,
7 SD, and 10 PD; the RR was 37.0% (10/27) and the
TSR was 63.0% (17/27). There were 7 PR, 10 SD, and
10 PD in the control group; the RR was 25.9% (7/27)Table 2
Comparison of the short-term efficacy between the two groups (n, %).
Groups CR PR SD
Combined treatment group (n ¼ 27)
2 cycles 0 (0) 10 (37.0) 7 (25.9
4 cycles 3 (11.1) 14 (51.6) 8 (29.6
Control group (n ¼ 27)
2 cycles 0 (0) 7 (25.9) 10 (37.0
4 cycles 0 (0) 8 (29.6) 9 (33.3
Compared with the control group after 2 cycles of treatment, aP > 0.05; com
complete remission; PR: partial remission; SD: stability of disease; PD: proand the TSR was 63.0% (17/27). Of 27 patients in the
combined treatment group after 4 cycles of treatment
there were 3 patients who had CR, 14 PR, 8 SD, and 2
PD; the RR was 63.0% (17/27), TSR was 92.6% (25/
27). There were 0 CR, 8 PR, 9 SD, and 10 PD in the
control group; the RR was 29.6% (8/27) and the TSR
was 63.0% (17/27). Both the RR and TSR of combined
treatment group were higher than in the control group
after 4 cycles of treatment and the differences were
significant (P < 0.05) (Table 2).
Safety evaluation: The adverse reactions of 54 pa-
tients can be evaluated and were mainly manifested as
alopecia, sore muscles and joints, and gastrointestinal
reactions, but there were no significant differences
between the two groups (P > 0.05). In addition, there
were 5 cases of electrocardiogram (ECG) changes
marked by T wave change, a slighter degree of ST-
segment depression, and nodal tachycardia, but the
symptoms returned to normal after drug discontinu-
ance or symptomatic treatment.
Comparison of the level of VEGF between two groups
There were no statistically significant differences
before treatment between the two groups (P> 0.05). The
level of VEGF after treatment in both groups signifi-
cantly decreased (P < 0.01). There were significantlyPD RR TSR
) 10 (37.0) 10 (37.0)a 17 (63.0)
) 2 (7.4) 17 (63.0) 25 (92.6)
) 10 (37.0) 7 (25.9)y 17 (63.0)
) 10 (37.0) 8 (29.6) 17 (63.0)
pared with control group after 4 cycles of treatment, yP < 0.05. CR:
gression of disease; RR: remission rate; TSR: total stability rate.
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cles of treatment. After 4 cycles of treatment, the VEGF
level in the trial group was significantly lower than in the
control group (P < 0.01) (Table 3).
Discussion
Most ovarian cancers are occult, about 75% patients
have been found with advanced disease. For advanced
ovarian cancer, cytoreductive surgery combined with
chemotherapy, usually platinum/paclitaxel, can
temporarily alleviate the condition, but the recurrence
rate is as high as 85%.6 Therefore, to explore a new
treatment of high specificity, limited side effects, and
with acceptable patient-tolerance is particularly
important. In recent years, a rapid development of
molecular targeted therapy for the treatment of
advanced ovarian cancer at home and abroad has
ushered in a new era.
Angiogenesis refers to the process of sprouting a
system of new blood vessels, mainly blood capillaries,
based on the existed microvascular bed. Under normal
physiological conditions, angiogenesis occurs only in
embryonic development and in the tissue injury repair
period, while the aberrant angiogenesis is one of the
pathological changes seen in tumors.2 Angiogenesis is
tightly regulated by a variety of angiogenic factors and
angiogenesis inhibitors, including VEGF and its re-
ceptor (VEGFR), considered to be the strongest and the
most specific key regulatory factors. It demonstrated
that the VEGF expression in the tumor was lower in
malignant tumors, borderline tumors, and benign tu-
mors, and in lymph node metastasis it is significantly
higher than in those without lymph node metastasis.7
The VEGF expression in ovarian cancer is signifi-
cantly higher than in normal ovarian tissue and benign
ovarian tumors, suggesting that VEGF plays a key role
in the development and progression of ovarian cancer.8
These findings provide evidence for treating ovarian
cancer by blocking VEGF expression. To determine
the efficacy of anti-tumor angiogenesis therapy, there
must be effective chemotherapy to decrease the tumor
burden, and the activity of tumor was significantly
decreased. The use of anti-tumor angiogenesis therapy
can block tumor angiogenesis, reduce the vascular
supply of the tumor, synergize with chemotherapy and
prolong its effective time.3 Bevacizumab is a new
molecular targeted drugs for anti-angiogenesis in phase
II and III clinical trials for the treatment of refractory
and recurrent ovarian cancer and ovarian cancer asso-
ciated with malignant ascites.9,10 It has achieved a
definite therapeutic effect.Rh-endosta is recombinant human rh-endostatin
developed in our country with multiple target points,
the mechanism of which is an anti-tumor effect by
inhibiting the migration of vascular endothelial cells and
blocking the tumor cell nutrient supply by acting on the
microenvironment of tumor cells, thus achieving the
purpose of inhibiting tumor growth or metastasis.11
Kisker et al12 found that with single rh-endostar intra-
peritoneal injection in a mouse, tumor tissue could be
cleared within 2 h. The use of a mini-osmotic pump for
continuous administration would make the plasma con-
centration stable for a long time, and 1/8 of the amount of
the injected dose can achieve the same anti-tumor effect.
This might be due to the ongoing administration of the
intravenous infusion, continuous uniform liquid input,
and extended infusion time that maintained a stable
blood concentration so that there was drug continually
presentation and neovascular endothelial cells were
exposed to a better anti-tumor effect.
This study compared the rh-endostar intravenous
infusion pump in combination with chemotherapy with
chemotherapy alone and compared the experimental
group and the control group, and the efficiency and the
overall stable rate have increased, and the difference
was significant (P < 0.05). Another study confirmed
that rh-endostar can inhibit ovarian cancer cells and
tumor growth, but rh-endostar intravenous infusion
studies on ovarian cancer therapy are few.13
Meanwhile, this study also measured patients' serum
VEGF levels. After both treatments, serum VEGF
levels were significantly lower than before (P < 0.05),
which was consistent with some other findings that
chemotherapy reduced the tumor burden and decreased
VEGF levels.14,15 This study found that after four cy-
cles of treatment, serum VEGF levels in the experi-
mental group decreased significantly more than in the
control group. This is evidence of rh-endostar's anti-
angiogenic effect via inhibition of VEGF expression.
The therapeutic effect may be due to the anti-tumor
effect of rh-endostar showing significant effect-time
dependence. With the extension of treatment time,
the anti-tumor effect was significantly higher. From a
retrospective analysis, the length of the rh-endostar
treatment period and sustaining its use would bring
greater benefits.16 Kubota17 showed that insufficient
anti-angiogenic drugs of a therapeutic dose could lead
to the rapid growth of blood vessels and limit the effect
of inhibiting tumor growth. Therefore, the long period
of rh-endostar application and subsequent maintenance
therapy may bring greater benefits to patients.
In conclusion, rh-endostatin intravenous infusion
combined with the TP regimen can enhance the
162 C. Zhang et al. / Chronic Diseases and Translational Medicine 1 (2015) 158e162efficacy of patients with advanced ovarian cancer and
reduce the adverse reactions. Further study also needs
long-term follow-up, a large-scale sample and a new
standard for judging the clinical efficacy.
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